Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treprostinil - United Therapeutics Corporation

Next Previous
Drug Profile

Treprostinil - United Therapeutics Corporation

Alternative Names: TD-300 TYVASO® Inhalation System; 15AU; 15AU81; ARD-1500; ARD-1550; BW 15AU; BW 15AU81; BW A15AU; LRX 15; MD 711; MD-0701; OreniCell; OreniLeft; Orenitram; Remodulin; Sustained-release treprostinil - United Therapeutics; TD-100 TYVASO® Inhalation System; TransCon treprostinil; Treprost; Treprostenol; Treprostinil diolamine; Treprostinol; Tresprostinol diethanolamine; Tyvaso; U 62840; Uniprost; UT 15; UT-15C; UT-15C SR

Latest Information Update: 05 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; Pfizer
  • Developer AOP Orphan Pharmaceuticals AG; Ascendis Pharma; Ferrer; Lee's Pharmaceutical; Mochida Pharmaceutical; United Therapeutics Corporation
  • Class Acetic acids; Antifibrotics; Antihypertensives; Antineoplastics; Cyclopentanes; Heart failure therapies; Naphthalenes; Prostaglandins; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Idiopathic pulmonary fibrosis; Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension; Pulmonary hypertension
  • Phase III Idiopathic pulmonary fibrosis
  • Phase II Systemic scleroderma
  • Discontinued Cancer; Chronic limb-threatening ischemia; Heart failure

Most Recent Events

  • 30 Jul 2025 United Therapeutics completes the Phase-III TETON 2 trial in Idiopathic pulmonary fibrosis in Argentina, Australia, Belgium, Chile, Denmark, France, Germany, Israel, Italy, Mexico, Netherlands, New Zealand, Peru, Spain, Taiwan, South Korea (Inhalation) (NCT05255991)
  • 31 Jan 2025 United Therapeutics Corporation completes enrolment in phase-III clinical trials in Idiopathic pulmonary fibrosis in Canada (Inhalation) (NCT04708782)
  • 22 Aug 2024 Liquidia Corporation files litigation in the US District Court of the District of Columbia, to challenge regulatory exclusivity to Tyvaso DPI®, blocking access to treprostinil inhalation powder (YUTREPIA™) for Pulmonary arterial hypertension

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top